Methods to study postprandial lipemia

Current Vascular Pharmacology

Volumn 9, Issue 3, 2011, Pages 302-308

  Ooi, Teik Chye ^a   Nordestgaard, Borge G ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Lipoprotein remnants; Markers of postprandial lipoproteins; Methodology; Postprandial lipemia; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B48; BIOLOGICAL MARKER; CHOLESTEROL; CHYLOMICRON; LIPOPROTEIN; STABLE ISOTOPE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; FAT INTAKE; FOOD INTAKE; GENETIC ANALYSIS; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; METHODOLOGY; POSTPRANDIAL STATE; QUANTITATIVE ANALYSIS;

ANIMALS; CHYLOMICRONS; DIETARY FATS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, VLDL; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 79955622682     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111795495567     Document Type: Article

References (80)

1. Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis 1981; 1: 38-49.
2. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res 1988; 29: 1491-500.
3. Ooi TC, Ooi DS. The atherogenic significance of an elevated plasma triglyceride level. Crit Rev Clin Lab Sci 1998; 35: 489-516.
4. Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 2006; 26: 773-86.
5. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005; 12: 1931-45.
6. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-53.
7. Griffin BA. Low-density lipoprotein subclasses: mechanisms of formation and modulation. Proc Nutr Soc 1997; 56: 693-702.
8. Brinton EA, Eisenberg S, Breslow JL. Increased apoA-I and apo AII fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991; 87: 536-44.
9. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by ApoA-1 fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arteriosclerosis and Thrombosis 1994; 14: 707-20.
10. Weinstein MM, Yin L, Wang X, Wu X, Castellani LW, Walzem RL. Chylomicronemia elicits atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2010; 30: 20-3.
11. Lairon D, DeFoort C. Effects of nutrients on postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 309-12.
12. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53.
13. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
14. Iso H, Naito Y, Sato S, et al. Serum triglyercides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001; 153: 490-9.
15. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with non-fasting lipids and apolipoprotein for predicting incident cardiovascular events. Circulation 2008; 118: 993-1001.
16. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23.
17. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
18. Bansai S, Buring JE, Rifai N. Fasting compared with non-fasting triglycerides and risk of cardiovascular events. JAMA 2007; 298: 309-16.
19. Patel A, Barzi F, Jamrozik K, et al. Serum triglyerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-86.
20. Freilberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Non-fasting triglyerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-51.
21. Stalenhoef AFH, de Graaf J. Association of fasting and non-fasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008; 19: 355-61.
22. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and non-fasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118: 2047-56.
23. Hoeg JM, Sviridov D, Tennyson GE, et al. Both apolipoproteins B-48 and B-100 are synthesized and secreted by the human intestine. J Lipid Res 1990; 31: 1761-9.
24. Havel R. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5: 102-9.
25. Phillips ML, Pullinger C, Kroes I, et al. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J Lipid Res 1997; 38: 1170-7.
26. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988; 29: 925-36.
27. Poapst M, Uffelman K, Steiner G. The chromogenicity and quantitation of apoB-100 and apoB-48 of human plasma lipoproteins on analytical SDS gel electrophoresis. Atheroscelerosis 1987; 65: 75-88.
28. Zilversmit DB, Shea TM. Quantitation of apoB-48 and apo-B100 by gel scanning or radio-iodination. J Lipid Res 1989; 30: 1639-46.
29. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fatcontaining meal in normolipidemic humans. Proc Natl Acad Sci USA 1993; 90: 2069-73.
30. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of Triglyceride-Rich Lipoproteins during alimentary lipemia. J Clin Invest 1993; 91: 748-58.
31. Jackson KG, Williams CM. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atheroscelerosis 2004; 176: 207-17.
32. Peel AS, Zampelas A, Williams CM, Gould BJ. A novel antiserum specific to apolipoprotein B-48: application in the investigation of postprandial lipidemia in humans. Clin Sc 1993; 85: 521-4.
33. Smith D, Proctor SD, Mamo JC. A highly sensitive assay for the quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997; 34: 185-9.
34. Su JW, Nzekwu MM, Cabezas MC, Redgrave T, Proctor SD. Methods to assess impaired post-prandial metabolism and the impact for early detecton of cardiovascular disease risk. Eur J Clin Invest 2009; 39: 741-54.
35. Lovegrove JA, Isherwood SG, Jackson KG, Williams CM, Gould BJ. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim Biophys Acta 1996; 1301: 221-9.
36. Uchida Y, Kurano Y, Ito S. Establishment of monoclonal antibody against human Apo B-48 and measurement of Apo B-48 in serum ELISA method. J Clin Lab Anal 1998; 12: 289-92.
37. Lorec A-M, Juhel C, Pafumi Y, et al. Determination of apolipoprotein B-48 in plasma by a competitive ELISA. Clin Chem 2000; 46: 1638-42.
38. Sakai N, Uchida Y, Ohashi K, et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003; 44: 1256-62.
39. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apoliporotein B-48 in serum by a sandwich ELISA. Clinica Chimica Acta 2005; 351: 115-20.
40. Karpe F, Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res 1995; 36: 1557-66.
41. Björkegren J, Packard CJ, Hamsten A, et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996; 37: 76-86.
42. van Beek AP, van Barlingen HH, de Ruijter-Heijstek FC, et al. Preferential clearance of apoB-48-containing lipoproteins after heparin-induced lipolysis is modulated by lipoprotein lipase activity. J Lipid Res 1998; 39: 322-32.
43. Berman M, Hall M, Levy RI, et al. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects. J Lipid Res 1978; 19: 38-56.
44. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991; 89: 109-16.
45. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, Type IIa, Type III, and Type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-9.
46. Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb 1992; 12: 1184-90.
47. Cohn JS, Johnson EJ, Millar JS, et al. Contribution of ApoB-48 and ApoB-100 Triglyceride-Rich Lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34: 2033-40.
48. Karpe F, Bell M, Björkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arteriosclerosis, Thrombosis and Vascular Biology 1995; 15: 199-207.
49. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. J Clin Invest 1988; 82: 1884-93.
50. Goodman DS. Vitamin A and retinoids: recent advances, introduction, background and general overview. Fed Proc 1979; 38: 2501-3.
51. Wilson DE, Chan I-F, Ball M. Plasma lipoprotein retinoids after vitamin A feeding in normal man: Minimal appearance of retinyl esters among low-density lipoproteins. Metabolism 1983; 32: 514-7.
52. Berr F, Kern FJ. Plasma clearance of chylomicrons labeled with retinyl palmitate in healthy human subjects. J Lipid Res 1984; 25: 805-12.
53. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans: A reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism 1990; 39: 357-65.
54. Smith JE, Goodman DS. Retinol-binding protein and the regulation of vitamin A transport. Fed Proc 1979; 38: 2504-9.
55. Sprecher DL, Knauer SL, Black DM, et al. Chylomicron-retinyl palmitate clearance in Type I hyperlipidemic families. J Clin Invest 1991; 88: 985-94.
56. Sauvant P, Mekki N, Charbonnier M, Portugal H, Lairon D, Borel P. Amounts and types of fatty acids in meals affect the pattern of retinoids secreted in human chylomicrons after a high-dose preformed vitamin A intake. Metabolism 2003; 52: 514-9.
57. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein apo A-1 production in human subjects using deuterated leucine. J Clin Invest 1990; 85: 804-11.
58. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 1999; 19: 2966-74.
59. Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, Klein S. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res 2002; 43: 223-33.
60. Lemieux S, Patterson BW, Carpentier A, Lewis GF, Steiner G. A stable isotope method using a [(2)H(5)]glycerol bolus to measure very low density lipoprotein triglyceride kinetics in humans. J Lipid Res 1999; 40: 2111-7.
61. Magkos F, Mittendorfer B. Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo. Clin Lipidol 2009; 4: 215-30.
62. Bickerton AS, Roberts R, Fielding BA, et al. Preferential uptake of dietary fatty acids in adipose tissue and muscle in the postprandial period. Diabetes 2007; 56: 168-76.
63. Chan DC, Watts GF. Recent advances in the investigation of lipoprotein metabolism using tracer methodology. Clin Lab 2006; 52: 353-61.
64. Nakajima K, Okazaki M, Tanaka A, et al. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to Apo B-100 and Apo A-1. J Clin Lig Assay 1996; 19: 177-83.
65. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-80.
66. Marcoux C, Tremblay M, Fredenrich A, et al. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atheroscelerosis 1998; 139: 161-71.
67. McNamara JR, Shah PK, Nakajima K, et al. Remnant Lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem 1998; 44: 1224-32.
68. Nakajima K, Nakano T, Moon HD, et al. The correlation between TG vs. remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers. Clin Chim Acta 2009; 404: 124-7.
69. van Oostrom AJ, Alipour A, Sijmonsma TP, et al. Comparison of different methods to investigate postprandial lipaemia. Neth J Med 2009; 67: 13-20.
70. Ooi TC, Cousins M, Ooi DS, et al. Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab 2001; 86: 3134-42.
71. Gavin C, Sigal RJ, Cousins M, et al. Resistance exercise but not aerobic exercise lowers remnant-like lipoprotein particle cholesterol in type 2 diabetes: A randomized controlled trial. Atherosclerosis 2010; 213: 552-7.
72. Miyauchi K, Kayahara N, Ishigami M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007; 53: 2128-35.
73. Nakada Y, Kurosawa H, Tohyama J, Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilising a newly developed remnant assay, remnant lipoprotein cholesterol homogenous assay (RemL-C). J Atheroscler Thromb 2007; 14: 56-64.
74. Yoshida H, Kurosawa H, Hirowatari Y, et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis 2008; 7: 1-5.
75. Hihara M, Sato I, Hayashi F, et al. Comparison of remnant lipoprotein-cholesterol measurements: the immune adsorption method (RLP-C) and the direct assay with detergent (RemL-C). Rinsho Byori 2009; 57: 24-30.
76. Schaefer EJ. Limitations of automated remnant lipoprotein cholesterol assay for diagnostic use. Clin Chem 2009; 55: 2061-2.
77. Cohen JC, Noakes TD, Benade AJ. Postprandial lipemia and chylomicron clearance in athletes and in sedentary men. Am J Clin Nutr 1989; 49: 443-7.
78. Park Y, Damron BD, Miles JM, Harris WS. Measurement of human chylomicron triglyceride clearance with a labeled commercial lipid emulsion. Lipids 2001; 36: 115-20.
79. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
80. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a metaanalysis. Curr Vasc Pharmacol 2011; 9: 271-80.